FindTrial
Sign In

INCAGN02390

DRUG7 trials

Sponsors

Incyte Corp., Incyte Biosciences International S.a.r.l., Incyte Corporation, Incyte Biosciences International Sàrl

Conditions

Cervical CancerEndometrial CancerEndometrial cancerEsophageal CancerGastric CancerGastroesophageal Junction CancerHead and Neck CancerHepatocellular Carcinoma

Phase 1

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
CompletedNCT03652077
Incyte CorporationCervical Cancer, Esophageal Cancer, Gastric Cancer +18
Start: 2018-09-24End: 2021-08-18Updated: 2021-11-15
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
CompletedNCT04370704
Incyte CorporationMelanoma
Start: 2020-07-27End: 2025-08-25Updated: 2025-10-03

Phase 2

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
Active, not recruitingNCT04463771
Incyte CorporationEndometrial Cancer
Start: 2021-01-26End: 2026-07-10Updated: 2025-12-10
An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
TerminatedNCT04586244
Incyte CorporationUrothelial Carcinoma
Start: 2022-01-14End: 2024-01-29Updated: 2025-10-30
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Active, not recruitingNCT05287113
Incyte Biosciences International SàrlHead and Neck Cancer
Start: 2022-11-14End: 2026-07-10Updated: 2026-03-27
INCMGA 0012-204: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)
Active, not recruitingCTIS2022-502600-79-00
Incyte Corp.Endometrial cancer
Start: 2021-03-16Target: 88Updated: 2025-09-24
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TIM-3) as First-Line Treatment in Participants With PD-L1–Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Active, not recruitingCTIS2023-504270-38-00
Incyte Biosciences International S.a.r.l.In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN.
Start: 2022-10-18Target: 66Updated: 2026-01-14

Related Papers

A phase 1/2 study of retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) combination therapy in patients (Pts) with advanced solid tumors.
Journal of Clinical Oncology2023-06-017 citations
Phase 2 trial of retifanlimab (anti–PD-1) in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti–TIM-3) as first-line treatment in patients with PD-L1–positive recurrent/metastatic squamous cell carcinoma of the head and neck.
Journal of Clinical Oncology2023-06-015 citations
Randomized phase 2 umbrella study of various neoadjuvant therapies for patients with muscle-invasive urothelial carcinoma of the bladder (MIBC) who are cisplatin-ineligible or refuse cisplatin therapy and undergoing radical cystectomy (Optimus).
Journal of Clinical Oncology2022-02-161 citations
348 A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204, GOG 3038, ENGOT-en12/NOGGO)
Regular and Young Investigator Award Abstracts2020-11-014 citations